179530 — ADBiotech Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩23bn
- KR₩25bn
- KR₩10bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | KAS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2,125 | 2,842 | 2,781 | 8,628 | 9,414 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,410 | 2,132 | 3,502 | 2,344 | 1,633 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 5,792 | 7,249 | 8,672 | 14,123 | 13,417 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,485 | 7,423 | 10,287 | 10,319 | 10,312 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 11,361 | 18,840 | 20,959 | 31,018 | 28,093 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4,306 | 5,495 | 12,626 | 11,793 | 12,990 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 4,374 | 9,513 | 15,854 | 14,833 | 14,701 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 6,987 | 9,327 | 5,106 | 16,185 | 13,393 |
Total Liabilities & Shareholders' Equity | 11,361 | 18,840 | 20,959 | 31,018 | 28,093 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |